CRMD: מכפיל P/S עתידי CorMedix Inc.

CorMedix Inc. (CRMD) is strengthening its position following FDA approval of Defencath, which guarantees demand and patent protection. The company occupies a unique niche by preventing bloodstream infections in clinical settings. The implementation of sterile fill-finish robotics with AI control optimizes production, supporting the forward P/S multiple on GURU.Markets, where the 0.90 level serves as a critical benchmark for the asset's current attractiveness.

The forward P/S ratio determines the market value of a business relative to expected sales, reflecting the consensus valuation of capitalization potential. For CorMedix Inc. (CRMD), this multiple accounts for the impact of robotizing Defencath filling lines, where the implementation of AI control reduces costs and scales revenue. By analyzing this forward P/S chart, an investor can identify whether the asset is overheated or if its technological advantage is undervalued. The metric's price action serves as a signal for adjusting the company's portfolio weighting.